386 related articles for article (PubMed ID: 15159443)
1. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Desta Z; Ward BA; Soukhova NV; Flockhart DA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
[TBL] [Abstract][Full Text] [Related]
2. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
3. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
Dehal SS; Kupfer D
Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
Crewe HK; Notley LM; Wunsch RM; Lennard MS; Gillam EM
Drug Metab Dispos; 2002 Aug; 30(8):869-74. PubMed ID: 12124303
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.
Parte P; Kupfer D
Drug Metab Dispos; 2005 Oct; 33(10):1446-52. PubMed ID: 15987777
[TBL] [Abstract][Full Text] [Related]
11. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
13. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
14. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
[TBL] [Abstract][Full Text] [Related]
16. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
17. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.
Coller JK; Krebsfaenger N; Klein K; Wolbold R; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
Br J Clin Pharmacol; 2004 Jan; 57(1):105-11. PubMed ID: 14678348
[TBL] [Abstract][Full Text] [Related]
18. The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro.
Ma J; Chu Z; Lu JBL; Liu J; Zhang Q; Liu Z; Tang D
Chem Biodivers; 2018 Jan; 15(1):. PubMed ID: 28834279
[TBL] [Abstract][Full Text] [Related]
19. Temsirolimus metabolic pathways revisited.
Shokati T; Hartmann M; Davari B; Klawitter J; Klawitter J; Christians U
Xenobiotica; 2020 Jun; 50(6):640-653. PubMed ID: 31596164
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor.
Obach RS; Margolis JM; Logman MJ
Drug Metab Pharmacokinet; 2007 Oct; 22(5):336-49. PubMed ID: 17965517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
